 |
|
|
|
 |
|
|
| Article 1 to 10 out of 37 concerning Dyax Corp.
|
-
Dyax Announces Completion of Biologics License Application for DX-88 for Hereditary Angioedema
(29 Sep 2008)
Dyax Corp. announced the completion of its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for approval of Dyax's lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). Dyax ...
-
Dyax Announces Final Patient Treated in Second Phase 3 Clinical Trial (EDEMA4) of DX-88 in Hereditary Angioedema
(26 Jun 2008)
Company's Clinical Research Provider, BattelleCRO, to Shut Down
Dyax Corp. announced that it has treated the final patient in its second Phase 3, 96-patient trial of DX-88, known as EDEMA4, for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare and life-threatening inflammatory ...
-
Dyax Corp. Announces Intent to Close Belgium Research Facility
(30 Apr 2008)
Dyax Corp. announced that the Board of Directors of its Belgian subsidiary, Dyax SA, has initiated discussions with its 24 employees as it considers a possible closure of the Liege-based research facility. The closure option would allow for ...
-
Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications
(28 Apr 2008)
Dyax Corp. and Cubist Pharmaceuticals, Inc. announced that they have signed an exclusive license and collaboration agreement for the development and commercialization of the intravenous formulation of DX-88 for the prevention of blood loss during ...
-
Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program
(03 Mar 2008)
Peptide ligand used in purification process during manufacture of Wyeth's XYNTHA
Dyax Corp. announced that Wyeth Pharmaceuticals, a division of Wyeth, recently received market approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free), a recombinant factor VIII ...
-
Dyax Enters Into Antibody Agreements with Sanofi-aventis for the Fully Human Monoclonal Antibody and Phage Display Technology
(13 Feb 2008)
Dyax Retains Co-development Rights and Profit Sharing for Certain Partner Programs
Dyax Corp. and sanofi-aventis announced that they have entered into agreements in which sanofi-aventis has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2240, as well ...
-
Dyax Corp. Announces Extension of Antibody Library Collaboration with ImClone Systems
(12 Nov 2007)
Dyax Corp. announced the extension of the antibody library collaboration with ImClone Systems Incorporated for the discovery of therapeutic antibodies. Under the terms of this agreement, ImClone will continue to have access to Dyax's proprietary ...
-
Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies
(07 Sep 2007)
Dyax Corp. announced that they have entered into an agreement with Bayer Schering Pharma AG for the discovery of therapeutic antibodies. Under the terms of this agreement, Dyax will identify therapeutic antibodies for two targets provided by Bayer ...
-
Dyax Corp. Licenses Antibody Phage Display Libraries to Cambridge Antibody Technology
(06 Aug 2007)
Dyax Corp. announced that they have licensed their antibody phage display libraries to Cambridge Antibody Technology (CAT), a wholly-owned subsidiary of AstraZeneca, for the discovery of therapeutic antibodies. CAT will receive sublicenses to ...
-
Organon and Dyax enter into therapeutic antibody alliance
(19 Jul 2007)
Organon announced that they have entered into an agreement with Dyax Corp. to discover and develop human therapeutic antibodies for the treatment of auto-immune diseases and cancer. Under the terms of the agreement, Dyax will utilize its proprietary ...
Additional information
Dyax Corp.
Cambridge, MA, United States of America
Company
|
|
|
|
|
|
Top
